<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01431430</url>
  </required_header>
  <id_info>
    <org_study_id>P100103</org_study_id>
    <nct_id>NCT01431430</nct_id>
  </id_info>
  <brief_title>VITamine D Supplementation in RenAL Transplant Recipients - VITALE</brief_title>
  <acronym>VITALE</acronym>
  <official_title>Prospective Double Blind Multicentre Randomized Trial of Vitamine D Estimating the Profit of a Treatment by Vitamin D3 at the Dose of 100000 UI by Comparison With a Treatment in the Dose of 12 000 UI at Renal Transplanted Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laboratoire Crinex</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It has been proposed that the intake of high dose of cholecalciferol may have beneficial non&#xD;
      classical effects (beside bone health). This could include the reduction of type 2 diabetes&#xD;
      mellitus, cardiovascular diseases, cancers, autoimmune and infectious diseases. These&#xD;
      pleiotropic effects are mostly documented by observational and experimental studies or small&#xD;
      intervention trials. In renal transplant recipients, vitamin D insufficiency, defined as&#xD;
      circulating 25(OH)vitamin D (25OHD) less than 30 ng/mL, is a frequent finding and this&#xD;
      population is at risk of the previously cited complications.The primary purpose of this study&#xD;
      is to compare the effects of high dose vs. low dose of cholecalciferol on a composite&#xD;
      endpoint consisting in de novo diabetes mellitus, cardiovascular diseases, de novo cancer and&#xD;
      patient death.Renal transplant recipients between 12 and 48 months after transplantation will&#xD;
      be randomized to blindly receive either high or low dose of cholecalciferol with a follow-up&#xD;
      of 2 years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale :&#xD;
&#xD;
      Vitamin D cannot be considered any more as only necessary to prevent rickets or osteomalacia.&#xD;
      Calcitriol produced in the kidney is known to have classical endocrine PHOSPHOCALCIC&#xD;
      properties. More recently, vitamin D has been shown to play an important role in reducing the&#xD;
      risk of many chronic diseases including type 2 diabetes mellitus, cardiovascular diseases,&#xD;
      cancers, autoimmune and infectious diseases. These effects may be secondary to local&#xD;
      production of calcitriol and to its autocrine and paracrine actions on cellular proliferation&#xD;
      and differentiation, apoptosis, insulin and renin secretion, interleukin and bactericidal&#xD;
      proteins production. These pleiotropic effects are mostly documented by observational and&#xD;
      experimental studies or small intervention trials that most often evaluated intermediate&#xD;
      parameters. In renal transplant recipients, vitamin D insufficiency (circulating 25OHD&lt;30&#xD;
      ng/mL or 75 nmol/L) , is a frequent finding with more than 80% of patients displaying this&#xD;
      profile.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      Primary objective: compare the effects of high dose vs. low dose of cholecalciferol on a&#xD;
      composite endpoint including&#xD;
&#xD;
        -  De novo diabetes mellitus (fasting glycemia &gt; 7 MMOLES/l or glycemia &gt; 11 MMOLES/l)&#xD;
&#xD;
        -  Cardiovascular complications (acute coronary heart disease, acute heart failure,&#xD;
           lower-extremity arterial disease, cerebrovascular disease).&#xD;
&#xD;
        -  De novo cancer,&#xD;
&#xD;
        -  Patient death.&#xD;
&#xD;
      Secondary objectives : compare the effects of high dose vs. low dose of cholecalciferol on&#xD;
&#xD;
        -  The occurrence of each event constituting the primary endpoint&#xD;
&#xD;
        -  Blood pressure and blood pressure control (number and dosage of antihypertensive drugs)&#xD;
&#xD;
        -  Echocardiography findings&#xD;
&#xD;
        -  Infection including opportunistic (CMV, pneumocystis, nocardial infection, cryptococcal&#xD;
           infection, aspergillosis)&#xD;
&#xD;
        -  Acute rejection episode&#xD;
&#xD;
        -  Renal allograft function including estimated glomerular filtration rate and proteinuria&#xD;
           - Graft survival&#xD;
&#xD;
        -  PHOSPHOCALCIC biological and clinical relevant parameters : Evolution of serum 25OHD,&#xD;
           calcaemia, phosphataemia, serum PTH, bone mineral density and incidence of fractures&#xD;
&#xD;
        -  Renal lithiasis&#xD;
&#xD;
      Study protocol&#xD;
&#xD;
      Number of patients: 320 patients in each group Inclusions : 2 years Follow-up after inclusion&#xD;
      : 2 years Prospective, randomized, multicentre, double blind clinical study comparing high&#xD;
      dose cholecalciferol [100 000 UI FORTHIGHTLY for 2 months then monthly for 22 months) vs. low&#xD;
      dose cholecalciferol [12 000 UI FORTHIGHTLY for 2 months then monthly for 22 months).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 6, 2012</start_date>
  <completion_date type="Actual">February 2, 2016</completion_date>
  <primary_completion_date type="Actual">February 2, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>De novo diabetes mellitus</measure>
    <time_frame>2 years</time_frame>
    <description>De novo diabetes mellitus (fasting glycemia &gt; 7 mmoles/l or glycemia &gt; 11 mmoles/l)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular complications</measure>
    <time_frame>2 years</time_frame>
    <description>Cardiovascular complications (acute coronary heart disease, acute heart failure, lower-extremity arterial disease, cerebrovascular disease).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>De novo cancer</measure>
    <time_frame>2 years</time_frame>
    <description>Diagnosis of the incidence of any new cancer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient death</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure control</measure>
    <time_frame>2 years</time_frame>
    <description>Blood pressure and blood pressure control (number and dosage of antihypertensive drugs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiography findings</measure>
    <time_frame>2 years</time_frame>
    <description>Comparison of left ventricular ejection fraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection including opportunistic</measure>
    <time_frame>2 years</time_frame>
    <description>Infection including opportunistic (CMV, pneumocystis, nocardial infection, cryptococcal infection, aspergillosis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute rejection episode</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal allograft function</measure>
    <time_frame>2 years</time_frame>
    <description>Renal allograft function including estimated glomerular filtration rate, proteinuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phosphocalcic biological and clinical relevant parameters</measure>
    <time_frame>2 years</time_frame>
    <description>PHOSPHOCALCIC biological and clinical relevant parameters : Evolution of serum 25OHD, calcaemia, phosphataemia, serum PTH, bone mineral density and incidence of fractures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal lithiasis</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">538</enrollment>
  <condition>Renal Transplant Candidate for Right Kidney</condition>
  <arm_group>
    <arm_group_label>Cholecalciferol 100 000 UI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cholecalciferol 100 000 UI FORTHIGHTLY for 2 months then monthly for 22 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cholecalciferol 12 000 UI (Control)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cholecalciferol 12 000 UI FORTHIGHTLY for 2 months then monthly for 22 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol 100 000 UI</intervention_name>
    <description>Cholecalciferol 100 000 UI FORTHIGHTLY for 2 months then monthly for 22 months</description>
    <arm_group_label>Cholecalciferol 100 000 UI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol 12 000 UI</intervention_name>
    <description>Cholecalciferol 12 000 UI FORTHIGHTLY for 2 months then monthly for 22 months.</description>
    <arm_group_label>Cholecalciferol 12 000 UI (Control)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Renal transplant recipients between 12 and 48 months after transplantation with a&#xD;
             stable renal function during the past 3 months.&#xD;
&#xD;
          -  Vitamine D insufficiency defined as a concentration of 25OHD lower than 30 ng/ml.&#xD;
&#xD;
          -  Patient between 18 and 75 years old&#xD;
&#xD;
          -  Patient capable of understanding the advantages and the risks of the study.&#xD;
&#xD;
          -  Affiliated with social security health insurance&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Calcaemia &gt; 2,7 mmol/l&#xD;
&#xD;
          -  Phosphataemia &gt; 1,5 mmol/l&#xD;
&#xD;
          -  Serum creatinine &gt; 250 µmol/l&#xD;
&#xD;
          -  Treatment by an active form of the vitamin D not being able to be interrupted&#xD;
&#xD;
          -  Transplant of an organ other than the kidney&#xD;
&#xD;
          -  Type I or type II diabetes mellitus&#xD;
&#xD;
          -  Past medical history of granulomatosis or active granulomatosis&#xD;
&#xD;
          -  Primary hyperoxaluria&#xD;
&#xD;
          -  Malabsorption proved by the liposoluble vitamins&#xD;
&#xD;
          -  Simultaneous participation in another therapeutic essay&#xD;
&#xD;
          -  Patients presenting a drug addiction or a psychiatric disorder&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Vitamin D hyper sensibility&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric THERVET, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>European Georges Pompidou Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georges Pompidou European Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>August 22, 2011</study_first_submitted>
  <study_first_submitted_qc>September 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2011</study_first_posted>
  <last_update_submitted>December 20, 2017</last_update_submitted>
  <last_update_submitted_qc>December 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamine D</keyword>
  <keyword>renal transplantation</keyword>
  <keyword>diabetes mellitus</keyword>
  <keyword>cancer</keyword>
  <keyword>cardiovascular complications</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

